BR0210976A - Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia - Google Patents

Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia

Info

Publication number
BR0210976A
BR0210976A BR0210976-0A BR0210976A BR0210976A BR 0210976 A BR0210976 A BR 0210976A BR 0210976 A BR0210976 A BR 0210976A BR 0210976 A BR0210976 A BR 0210976A
Authority
BR
Brazil
Prior art keywords
once daily
therapy
carvedilol
daily therapy
pharmaceutical composition
Prior art date
Application number
BR0210976-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Dilip Shantilal Shanghvi
R Bala Ramesha Chary
Z Ziauddin Tyebji
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR0210976A publication Critical patent/BR0210976A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Packaging Frangible Articles (AREA)
BR0210976-0A 2001-05-17 2002-05-10 Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia BR0210976A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN464MU2001 IN191028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-05-17 2001-05-17
PCT/IN2002/000118 WO2002092078A1 (en) 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Publications (1)

Publication Number Publication Date
BR0210976A true BR0210976A (pt) 2004-10-05

Family

ID=11097247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210976-0A BR0210976A (pt) 2001-05-17 2002-05-10 Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia

Country Status (16)

Country Link
US (1) US20030035836A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1395258A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2004534031A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20040037026A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1525855A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2002314515B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1014328A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0210976A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2447005A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0400607A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN191028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA03010501A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL370589A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2003133446A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2002092078A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200309724B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1067910B1 (en) 1998-04-03 2004-05-26 Egalet A/S Controlled release composition
EP1929998A3 (en) * 2001-09-21 2008-11-26 Egalet A/S Controlled release solid dispersions of carvedilol
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
NZ537161A (en) 2002-06-27 2007-09-28 Sb Pharmco Inc Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
AU2003251627A1 (en) 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
US20060258652A1 (en) * 2002-11-22 2006-11-16 Haj-Yehia Abdullah I Beta-blockers having antioxidant and no-donor activity
ATE399538T1 (de) 2003-03-26 2008-07-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
DK1615626T3 (da) * 2003-04-24 2010-02-08 Jagotec Ag Tablet med farvet kerne
US7260685B2 (en) 2003-06-20 2007-08-21 Micron Technology, Inc. Memory hub and access method having internal prefetch buffers
EP3578175B1 (en) * 2003-09-12 2022-11-30 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
US7120743B2 (en) 2003-10-20 2006-10-10 Micron Technology, Inc. Arbitration system and method for memory responses in a hub-based memory system
ES2662903T3 (es) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited Base libre de carvedilol, sales, formas anhidras o solvato de la misma, composiciones farmacéuticas correspondientes, formulaciones de liberación controlada, y procedimientos de tratamiento o administración
JP2007512372A (ja) 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
NZ563846A (en) * 2005-06-03 2010-03-26 Egalet As A drug delivery system for delivering active substances dispersed in a dispersion medium
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
JP2009545546A (ja) 2006-08-03 2009-12-24 ニテック ファーマ アクチエンゲゼルシャフト リウマチ性疾患の遅延放出型グルココルチコイド治療
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
WO2011102504A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
ES2600894T3 (es) * 2010-02-22 2017-02-13 Daiichi Sankyo Company, Limited Preparación sólida de liberación sostenida para uso oral
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.
TWI566786B (zh) 2012-09-03 2017-01-21 第一三共股份有限公司 含有氫化嗎啡酮鹽酸鹽之經口用徐放性醫藥組成物
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CA2285407C (en) * 1997-03-11 2006-08-01 Darwin Discovery Limited Dosage forms comprising separate portions of r- and s-enantiomers
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
EP1233768A1 (en) * 1999-11-15 2002-08-28 Smithkline Beecham Carvedilol methanesulfonate
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
DE60105996T2 (de) * 2000-04-03 2006-03-09 F. Hoffmann-La Roche Ag Konzentrierte lösungen von carvedilol
CA2426811A1 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol

Also Published As

Publication number Publication date
IN191028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2003-09-13
BE1014328A7 (fr) 2003-08-05
JP2004534031A (ja) 2004-11-11
HUP0400607A2 (hu) 2004-07-28
EP1395258A1 (en) 2004-03-10
US20030035836A1 (en) 2003-02-20
RU2003133446A (ru) 2005-03-10
ZA200309724B (en) 2005-05-25
KR20040037026A (ko) 2004-05-04
AU2002314515B2 (en) 2007-08-16
HUP0400607A3 (en) 2005-07-28
MXPA03010501A (es) 2004-03-02
CN1525855A (zh) 2004-09-01
CA2447005A1 (en) 2002-11-21
WO2002092078A1 (en) 2002-11-21
PL370589A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
BR0210976A (pt) Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia
Brahmkshatriya et al. Clinical evaluation of Cissus quadrangularis as osteogenic agent in maxillofacial fracture: A pilot study
DK1623703T3 (da) Hydrocodonformuleringer med kontrolleret frigivelse
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
KR970061244A (ko) 치매 치료용 약학 조성물
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação
BR0309595A (pt) Injeção produzida a partir de ixeris sonchifolia hance para o tratamento de doenças vasculares cardiocerebrais e doenças de fundo, e método para a produção da mesma
Du Cayla et al. Long-term effectiveness and side effects of mandibular advancement devices on dental and skeletal parameters
Rizer et al. Macroglossia: etiologic considerations and management techniques
BR0016918A (pt) Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas
Kapetanakos et al. Rehabilitation of a patient after a total maxillectomy with a 2-piece magnetically retained obturator: A clinical report
Varma et al. Dermatomyositis‐like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
Kumar et al. Management of postburn perioral contracture using a customized static commissural splint and intralesional injections of triamcinolone
US20030109495A1 (en) Nutraceutical solutions comprising dimethyl sulfoxide
Deepika et al. Application of Polyvinyl chloride sheet as delayed surgical obturator in maxillectomy defects secondary to mucormycosis-A case series
Savion et al. Construction of a surgical stent for posttraumatic nasal synechia
Wei et al. Esthetic outcomes of counterclockwise maxillomandibular advancement for middle aged Chinese severe obstructive sleep apnea patients
Güvenç et al. Adverse Reaction to Customized Composite Peek Abutment: Case report
Turk et al. Comparison of acrylic/monolithic zirconia superstructures in all-on-4 concept
Doludeniz et al. Hemimasticatory Spasm: Treatment with Low-Level Laser Therapy
KR890015743A (ko) 근섬유아세포의 작용을 개선시키기 위한 tp-수용체 길항제의 용도
Venema et al. 0592 DENTAL SIDE EFFECTS OF LONG TERM OBSTRUCTIVE SLEEP APNEA THERAPY. A 10 YEAR FOLLOW UP STUDY

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.